Literature DB >> 19067252

Vascular disease in scleroderma.

Fredrick M Wigley1.   

Abstract

Although scleroderma is generally considered a fibrosing disease of the tissues, it is now recognized that the underlying vascular disease is playing a fundamental role in its pathogenesis and associated tissue injury. The exact mechanism for the widespread scleroderma vascular disease is still unknown, but endothelial cell injury induced by infection, immune-mediated cytotoxicity, antiendothelial antibodies, and/or ischemia-reperfusion have all been implicated. The downstream effects of blood vessel perturbation produce "biomarkers" of vascular damage that reflect disease and may predict clinical outcomes. A complex interaction between endothelial cells, smooth muscle cells, extracellular matrix, and intravascular circulating factors is now recognized to contribute to the vascular reactivity, remodeling, and occlusive disease of scleroderma. Understanding the mechanisms underlying these processes provides rationale of novel therapeutic strategies and specific targeted therapy. This review will outline some of the evidence for the causes and consequences of scleroderma vascular disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19067252     DOI: 10.1007/s12016-008-8106-x

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  331 in total

1.  Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma.

Authors:  R R Freedman; R Girgis; M D Mayes
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

2.  Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon.

Authors:  Madeleine Meli; Gabriela Gitzelmann; Renate Koppensteiner; Beatrice R Amann-Vesti
Journal:  Clin Rheumatol       Date:  2005-06-11       Impact factor: 2.980

3.  Antiphospholipid syndrome associated with progressive systemic sclerosis.

Authors:  W H Chun; D Bang; S K Lee
Journal:  J Dermatol       Date:  1996-05       Impact factor: 4.005

4.  Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera.

Authors:  M B Kahaleh; P S Fan
Journal:  Clin Immunol Immunopathol       Date:  1997-04

5.  Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma.

Authors:  S Majewski; N Hunzelmann; J P Johnson; C Jung; C Mauch; H W Ziegler-Heitbrock; G Riethmüller; T Krieg
Journal:  J Invest Dermatol       Date:  1991-10       Impact factor: 8.551

6.  Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis.

Authors:  C A Penning; J Cunningham; M A French; G Harrison; N R Rowell; P Hughes
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

7.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  David B Badesch; Nicholas S Hill; Gary Burgess; Lewis J Rubin; Robyn J Barst; Nazzareno Galiè; Gerald Simonneau
Journal:  J Rheumatol       Date:  2007-11-01       Impact factor: 4.666

8.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

Review 9.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Authors:  H Sallam; T A McNearney; J D Z Chen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

10.  A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma).

Authors:  C G P Roberts; L K Hummers; W J Ravich; F M Wigley; G M Hutchins
Journal:  Gut       Date:  2006-03-09       Impact factor: 23.059

View more
  31 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

2.  Cyclophosphamide: a novel treatment of gastric antral vascular ectasia associated with systemic sclerosis?

Authors:  Alicia Peterson; John Varga
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 3.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

4.  Cryoglobulinemic vasculitis in systemic sclerosis successfully treated with mycophenolate mofetil.

Authors:  Predrag Ostojic
Journal:  Rheumatol Int       Date:  2012-12-28       Impact factor: 2.631

5.  Oxidized low-density lipoprotein alters the effect of matrix stiffness on the formation of endothelial networks and capillary lumens.

Authors:  Madhu S Gundavaram; Tzu Pin Shentu; Gregory B Kowalsky; Suncica Volkov; Dean E Schraufnagel; Irena Levitan
Journal:  Pulm Circ       Date:  2013-12-05       Impact factor: 3.017

Review 6.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

7.  Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension.

Authors:  Ami A Shah; Fredrick M Wigley; Laura K Hummers
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

8.  Vasculitis in systemic sclerosis.

Authors:  Lily Kao; Cornelia Weyand
Journal:  Int J Rheumatol       Date:  2010-09-30

9.  Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series.

Authors:  Julie J Paik; Ram Hirpara; Jennifer A Heller; Laura K Hummers; Fredrick M Wigley; Ami A Shah
Journal:  Semin Arthritis Rheum       Date:  2016-03-31       Impact factor: 5.532

10.  Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.

Authors:  F Cozzi; E Pigatto; M Rizzo; M Favaro; E Zanatta; S Cardarelli; L Riato; L Punzi
Journal:  Clin Rheumatol       Date:  2013-01-24       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.